FDA Approves First Oral Treatment For Crohn's Disease, Making Seventh Approval For AbbVie's Rinvoq
Portfolio Pulse from Vandana Singh
The FDA has approved AbbVie's Rinvoq (upadacitinib) as the first oral treatment for moderately to severely active Crohn's disease patients. This marks the seventh FDA approval for Rinvoq across rheumatology, dermatology, and gastroenterology. Rinvoq competes with other biologics such as Johnson & Johnson's Stelara and Takeda Pharmaceutical's Entyvio.
May 19, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AbbVie's Rinvoq approval may increase competition for Johnson & Johnson's Stelara in the Crohn's disease treatment market.
The FDA approval of Rinvoq as the first oral treatment for Crohn's disease may increase competition for Johnson & Johnson's Stelara. This could potentially affect Stelara's market share and revenue, leading to a negative short-term impact on Johnson & Johnson's stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
NEGATIVE IMPACT
Takeda Pharmaceutical's Entyvio may face increased competition in the Crohn's disease treatment market due to AbbVie's Rinvoq approval.
The FDA approval of Rinvoq as the first oral treatment for Crohn's disease may increase competition for Takeda Pharmaceutical's Entyvio. This could potentially affect Entyvio's market share and revenue, leading to a negative short-term impact on Takeda Pharmaceutical's stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
AbbVie's Rinvoq receives FDA approval as the first oral treatment for Crohn's disease, expanding its indications across rheumatology, dermatology, and gastroenterology.
The FDA approval of Rinvoq as the first oral treatment for Crohn's disease is a significant milestone for AbbVie. This expands Rinvoq's indications across various fields, potentially increasing its market share and revenue. The approval is likely to have a positive short-term impact on AbbVie's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100